Retrospective efficacy and safety analyses of erlotinib, pemetrexed, and docetaxel in EGFR-mutation-negative patients with previously treated advanced non-squamous non-small-cell lung cancer

Lung Cancer

Volumn 89, Issue 3, 2015, Pages 301-305

  Nishiyama, Akihiro ^a   Katakami, Nobuyuki ^b   Yoshioka, Hiroshige ^a   Iwasaku, Masahiro ^a   Korogi, Yohei ^a   Hata, Akito ^b   Takeshita, Jumpei ^b   Otsuka, Kojiro ^c   Nishino, Kazumi ^d   Uchida, Junji ^d   Okuyama, Takako ^d   Namba, Yoshinobu ^e   Mori, Masahide ^e   Fujita, Shiro ^b   Morita, Satoshi ^f  

^a KURASHIKI CENTRAL HOSPITAL   (Japan)

^b INSTITUTE OF BIOMEDICAL RESEARCH AND INNOVATION   (Japan)

^c KOBE CITY MEDICAL CENTER GENERAL HOSPITAL   (Japan)

^d OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

^e TONEYAMA NATIONAL HOSPITAL   (Japan)

^f KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Docetaxel; EGFR mutation negative; Erlotinib; Non squamous non small cell lung cancer; Pemetrexed; Performance status; Second line treatment

Indexed keywords

DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; PEMETREXED; ANTINEOPLASTIC AGENT; TAXOID;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CANCER THERAPY; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CLINICAL ASSESSMENT; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; COMPARATIVE STUDY; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; FEBRILE NEUTROPENIA; FEMALE; GENE MUTATION; HUMAN; KIDNEY DISEASE; LEUKOPENIA; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROPENSITY SCORE; RETROSPECTIVE STUDY; SQUAMOUS CELL LUNG CARCINOMA; THROMBOCYTOPENIA; TREATMENT RESPONSE; WILD TYPE; CANCER STAGING; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIAL; GENETICS; KAPLAN MEIER METHOD; LUNG NEOPLASMS; METASTASIS; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; MUTATION; PATHOLOGY; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; ERLOTINIB HYDROCHLORIDE; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; NEOPLASM METASTASIS; NEOPLASM STAGING; PEMETREXED; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES; TAXOIDS; TREATMENT OUTCOME;

EID: 84938746202     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2015.06.017     Document Type: Article

References (17)

1. Azzoli C.G., Temin S., Aliff T., et al. Focused update of 2009 American Society of Clinical Oncology clinical practice guideline update on chemotherapy for stage IV non-small-cell lung cancer. J. Clin. Oncol. 2011, 29(35):4725.
2. Peters S., Adjel A.A., Gridelli C., et al. Metastatic non-small-cell lung cancer (NSCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2012, 23(Suppl. 7):vii56-vii64.
3. National Comprehensive Cancer Network Inc. NCCN Practice Guidelines in Oncology; Non-Small Cell Lung Cancer-v.2 2013, http://www.nccn.org/professionals/physician_gls/PDF/nscl.pdf.
4. Zhou C., Wu Y.L., Chen G., et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicenter, open-label, phase 3 study. Lancet Oncol. 2011, 12:735-742.
5. Rosell R., Carcereny E., Gervais R., et al. Erlotinib versus chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicenter, open-label, phase 3 study. Lancet Oncol. 2012, 13:239-246.
6. Yoshioka H., Hotta K., Kiura K., et al. A phase 2 trial of erlotinib monotherapy in pretreated patients with advanced non-small cell lung cancer who do not possess active EGFR mutations: Okayama Lung Cancer Study Group trial 0705. J. Thorac. Oncol. 2010, 5(1):99-104.
7. Zhu C., Santos G.C., Ding K., et al. Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. J. Clin. Oncol. 2008, 26:4268-4275.
8. Cappuzzo F., Ciuleanu T., Stelmakh L., et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicenter, randomised, placebo-controlled phase 3 study. Lancet Oncol. 2010, 11:521-529.
9. Ciuleanu T., Stelmakh L., Ciceanas S., et al. Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicenter, open-label, phase 3 study. Lancet Oncol. 2012, 13:300-308.
10. Scagliotti G.V., Parikh P., von Pawel J., et al. Phase 3 study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naïve patients with advanced-stage NSCLC. J. Clin. Oncol. 2008, 26(21):3543-3551.
11. Paz-Ares L., de Marinis F., Dediu M., et al. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial. Lancet Oncol. 2012, 13:247-255.
12. Nagai Y., Miyazaki H., Huqun, et al. Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nuclei acid-locked nucleic acid PCR clamp. Cancer Res. 2005, 65:7276-7282.
13. Rosenbaum P., Rubin D.B. The central role of the propensity score in observational studies for causal effects. Biometrika 1983, 70:41-55.
14. Garassino M.C., Martelli O., Broggini M., et al. Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumors (TAILOR): a randomised control trial. Lancet Oncol. 2013, 22.
15. Kawaguchi T., Ando M., Asami K., et al. Randomized phase III trial of erlotinib (E) versus docetaxel (D) as second- or third-line therapy in patients with advanced non-small cell lung cancer: Docetaxel and Erlotinib Lung Cancer Trial (DELTA). J. Clin. Oncol. 2014, 32(June (18)):1902-1908.
16. Chen G., Feng J., Zhou C., et al. Quality of life (QoL) analyses from OPTIMAL (CTONG-0802), a phase III, randomised, open-label study of first-line erlotinib versus chemotherapy in patients with advanced EGFR mutation-positive non-small-cell lung cancer (NSCLC). Ann. Oncol. 2013, 24(6):1615-1622.
17. Gaofeng P., Shaobo K., Zhao J. Comparison of the efficacy and safety of single-agent erlotinib and doublet molecular targeted agents based on erlotinib in advanced non-small cell lung cancer (NSCLC): a systematic review and meta-analysis. Target. Oncol. 2013, 8(June (2)):107-116.